Sanofi allergy drug safe enough for non-prescription use: FDA reviewers
WASHINGTON (Reuters) - Sanofi SA's allergy drug Nasacort AQ is safe enough to be sold over the counter, according to reviewers for the U.S. Food and Drug Administration.
The reviewers, whose opinions were posted on Monday on the FDA's website, said the nasal spray, which currently requires a prescription for use, "has a favorable risk-benefit profile" for use in an over-the-counter setting.
The documents were posted ahead of a meeting on Wednesday of an advisory committee to the FDA which will recommend whether or not the agency should approve the switch to over-the-counter use. The drug is used to treat hay fever and other respiratory allergies.
(Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick)
- Thousands of Gaza civilians flee after Israeli warning |
- Russia warns Ukraine after shell crosses border |
- Three dead, two wounded in Pasadena, California shootings
- As some high-risk assets take a hit, investors fear worse is to come
- Heavy fighting breaks out near Libya's Tripoli airport, seven dead
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video